Background.-Sexual dysfunction (SD) is highly prevalent in patients with multiple sclerosis (MS), affecting 50% to 80% of both male and female patients, and has a major impact on quality of life. Men present with erectile and ejaculatory dysfunctions (retarded, premature or anejaculation), and partial loss of libido. This leads to decreased frequency of intercourse, difficulty with achieving orgasm, and dissatisfaction with sexual performance.
Discussion.-Therapeutic management of urinary disorders is important in term of quality of life improvement. Access to medical treatment is actually limited despite numerous innovative treatments at each stage of the disease. Early diagnostic, appropriate follow-up and multidisciplinary approach guaranty the best management. Background.-Sexual dysfunction (SD) is highly prevalent in patients with multiple sclerosis (MS), affecting 50% to 80% of both male and female patients, and has a major impact on quality of life. Men present with erectile and ejaculatory dysfunctions (retarded, premature or anejaculation), and partial loss of libido. This leads to decreased frequency of intercourse, difficulty with achieving orgasm, and dissatisfaction with sexual performance.
Results.-Women commonly report reduced genital sensation, reduced vaginal lubrication, difficulty with arousal, and difficulty reaching orgasm. In both sexes, fatigue, spasticity, hand tremors, neuropathic pain, and anxiety about incontinence contribute to SD. Psychosocial and cultural issues also need evaluating, and include depression, performance anxiety, changes in family roles, lowered self-esteem, loss of confidence. In men, treatments are similar to that of other neurological diseases: erectile dysfunction can be treated with phosphodiesterase inhibitors and intracavernosus injections, though with limited efficacy. Multiple sclerosis (MS) is a chronic immune mediated disease affecting the central nervous system, and characterized by demyelination and axonal damage. The estimated prevalence of MS is approximately 2.5 million cases worldwide and the disease is the first most common cause of neurological disability in young adults. If untreated, MS typically leads to substantial accumulation of both physical and cognitive disability over time. For that reason, early use of disease-modifying therapies is required. These treatments should reduce relapse rate, limit the onset of new demyelinating lesions and postpone the development of long-term disability. Currently first-line-approved immunomodulator therapies for MS reduce disease activity and the accumulation of disability in relapsing remitting MS. Although these first-line treatments have shown excellent safety profiles, their effects are modest and all have to be given by injection. Immunosuppressive drugs are also approved for treatment of MS as secondline therapy, demonstrating greater efficacy but also many severe safety adverse events. Thus, there remains an unmet need for the development of more effective and well-tolerated oral therapies for the treatment of MS. Based on results of large randomized controlled trials, a number of oral medications have already been or will be approved. and structural MRI were performed at inclusion, just after rehabilitation, and three months after the end of rehabilitation. Topology of brain networks was analysed based on graph-theory method applied to rs-fMRI data. Morphological variations in grey matter (GM) were determined using longitudinal Voxel-Based Morphometry method applied to 3D T1-weighted images.
Discussion.-Graph-theory analysis evidenced after rehabilitation an increase of the local connectivity in the default mode network (DMN) and the central executive network (CEN). The amount of connectivity changes depicted in the DMN and the CEN was correlated to the clinical improvement. Structural MRI evidenced a significant increase in GM density in the left fronto-orbital cortex immediately after rehabilitation correlating with clinical improvement. After the end of rehabilitation, structural and functional brain reorganization progressively disappeared and clinical performances returned to baseline level. Multiple sclerosis is an inflammatory disease of central nervous system with both scattered and evolutive lesions. It is characterized by the appearance at a time variable in the development of disorders of balance and gait moving towards progressive disability. In MS, balance impairment is responsible for falls that occur at different stages of the disease. Imbalance and falls are related not only to impairment of motor control but also of the proprioception, the cerebellar function and vision. Spasticity and cognitive troubles have also been related to increased risk of falls.
